Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of Different Doses of Ruxolitinib as a Salvage Therapy for Refractory/Relapsed Hemophagocytic Lymphohistiocytosis

NCT04120090 is registered in ClinicalTrials.gov with Beijing Friendship Hospital as lead sponsor.

NCT NCT04120090
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04120090 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of Different Doses of Ruxolitinib as a Salvage Therapy for Refractory/Relapsed Hemophagocytic Lymphohistiocytosis
Lead sponsor
Beijing Friendship Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
July 1, 2019
Completion date
July 1, 2020
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hemophagocytic lymphohistiocytosis